Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
March 3, 2026
Inhibitory effect of Anwulignan on the IL-36R/TLR9 signaling pathway: potential therapeutic role in hepatic fibrosis
SY
Shang Yue
Dalian Medical University
YP
Yan-Gui Peng
Dalian Medical University
YW
Yan Wang
Dalian Ocean University
See all
Key Points
Anwulignan inhibits the IL-36R/TLR9 signaling pathway, reducing hepatic fibrosis.
The study observes a notable decrease in fibrosis markers with Anwulignan treatment.
This involves an analysis using animal models to explore therapeutic effects.
Highlighting the potential role of Anwulignan, further validation in human models is warranted.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Yue et al. (Fri,) studied this question.
synapsesocial.com/papers/69a767eebadf0bb9e87e2ed0
https://doi.org/https://doi.org/10.1016/j.phymed.2026.157931
Inhibitory effect of Anwulignan on the IL-36R/TLR9 signaling pathway: potential therapeutic role in hepatic fibrosis | Synapse